Analyst: FDA guidance will slow near-term adoption of wearables

Draft FDA guidance on the difference between "wellness" and "medical" devices will slow adoption of wearables by biopharma in the near term, according to an analyst. Juniper Research analyst James Moar told Outsourcing-Pharma the placing of limits on the types of information that can have medical uses will slow uptake. Article

Suggested Articles

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

Elligo Health Research will test a harmonized real-word data model built by the FDA.

Just about a year after filing its IPO application BGI hits a big wall with a regulatory review.